How Gline was paid
$3.1M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Matthew GlineChief Executive Officer | $725,000 | $2,359,250 | — | — | $11,940 | $3,096,190 |
| Richard PulikChief Financial Officer | $450,883 | $1,277,130 | $1,420,299 | $1,018,269 | $24,021 | $4,190,602 |
| Mayukh SukhatmePresident and Chief Investment Officer | $550,000 | $704,000 | — | — | $22,655 | $1,276,655 |
| Eric VenkerPresident and Immunovant CEO | $75,000 | $1,899,316 | $2,261,908 | — | $20,163,986 | $24,400,210 |
| Frank TortiPresident and Vant Chair | $725,000 | $8,428,000 | $109,338,796 | — | $4,808,770 | $123,300,566 |
What changed and why
- $3.1M$3,096,190 was CEO total compensation in Fiscal 2025, down from $163,293,744 in Fiscal 2024.
- $1.4M$1,431,250 was Gline’s remaining retention award payment, fully vesting on September 19, 2025.
- $123.3M$123,300,566 was Torti’s total compensation, including $109,338,796 in stock awards.
- $7.5M$7,500,000 was Torti’s one-time lump-sum cash retention award.
- $377K8.2:1 was the CEO-to-median-employee pay ratio, with median compensation of $377,109.
- 60.9%60.9% supported say-on-pay at the Fiscal 2024 annual meeting, down from 89.3% the prior year.
Other Roivant Sciences proxy statements
- 2025 proxy statement
Matthew Gline paid $163.3M, pay ratio 518:1.
Filed Jul 29, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.